CymaBay Therapeutics, Inc

Avirmax Inc, located in Hayward, CA, specializes in AAV engineering technology platforms and offers a range of biopharmaceutical products. The company is committed to fostering partnerships and is actively seeking talent for various career opportunities. With a focus on business development and media relations, Avirmax Inc welcomes inquiries to explore collaborative ventures and innovative solutions in the field of biopharma. Their dedication to advancing AAV technology positions them as a noteworthy entity in the biopharmaceutical industry. Generated from the website

Exelixis is an integrated drug discovery and development company. The company utilizes cutting-edge genomic, molecular biology and combinatorial chemistry technologies to develop innovative therapies for significant human diseases. Its primary mission is to improve patient care by developing proprietary human therapeutics that target the complex molecular causes of disease. Exelixis has built a research and discovery platform. The Exelixis clinical development pipeline includes compounds in cancer and renal disease. The company s pre-clinical pipeline is comprised of six programs. The pre-clinical oncology programs consist of development candidates that focus on inhibiting kinases. In its pre-clinical metabolic disease programs, Exelixis has developed small molecules that modulate nuclear hormone receptors that implicate various metabolic and cardiovascular disorders. Corporate headquarters are in San Francisco. The research facility is in Portland, Ore.

SuperGen, Inc., a pharmaceutical company, engages in the development and commercialization of the therapies for solid tumors, hematological malignancies, and blood disorders. The company offers Orathecin capsules, a second-generation topoisomerase I inhibitor, which causes single-strand breaks in the DNA of rapidly dividing tumor cells; Dacogen, a pyrimidine analog that decreases the amount of methylation at certain DNA sites; and Nipentis that is used for the treatment of hairy cell leukemia, a type of B-lymphocytic leukemia, as well as shows activity in various autoimmune diseases, including GvHD, bone marrow transplantation and multiple sclerosis. It also offers Mitomycin, Paclitaxel, Mitozytrex, Inhaled Orathecin, Partaject Orathecin, CZ 112, and Cremophor-free paclitaxel for solid tumors; Daunorubicin for Acute leukemias; Surface Safe for surface decontaminate; Partaject busulfan for Neoplastic meningitis/bone marrow transplant; Avicine for Therapeutic Vaccine; and VEGF for anti-angiogenesis. The company sells its products to cancer hospitals, clinics, private practice oncology clinics, oncology distributors, and drug wholesalers in the United States. SuperGen was founded in 1991 and is headquartered in Dublin, California.